Plus Therapeutics Inc [PSTV] stock is trading at $0.56, up 39.29%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PSTV shares have gain 30.60% over the last week, with a monthly amount glided 11.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Plus Therapeutics Inc [NASDAQ: PSTV] stock has seen the most recent analyst activity on September 03, 2025, when D. Boral Capital upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, D. Boral Capital started tracking the stock with Buy rating on March 17, 2025, and set its price target to $9. On January 25, 2021, Ladenburg Thalmann initiated with a Buy rating and assigned a price target of $8 on the stock. Maxim Group started tracking the stock assigning a Buy rating and suggested a price target of $6 on October 16, 2020.
Plus Therapeutics Inc [PSTV] stock has fluctuated between $0.16 and $2.31 over the past year. Plus Therapeutics Inc [NASDAQ: PSTV] shares were valued at $0.56 at the most recent close of the market.
Analyzing the PSTV fundamentals
Plus Therapeutics Inc [NASDAQ:PSTV] reported sales of 5.32M for the trailing twelve months, which represents a growth of 8.68%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -2.4%, Pretax Profit Margin comes in at -3.58%, and Net Profit Margin reading is -3.58%. To continue investigating profitability, this company’s Return on Assets is posted at -1.84, Equity is 2.19 and Total Capital is -4.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4913 points at the first support level, and at 0.4196 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6284, and for the 2nd resistance point, it is at 0.6938.
Ratios To Look Out For
For context, Plus Therapeutics Inc’s Current Ratio is 1.20. Further, the Quick Ratio stands at 1.20, while the Cash Ratio is 0.31. Considering the valuation of this stock, the price to sales ratio is 10.50, the price to book ratio is 17.11.
Transactions by insiders
Recent insider trading involved Lenk Robert P, Director, that happened on Aug 22 ’25 when 0.11 million shares were purchased. Director, Petersen Greg completed a deal on May 15 ’25 to buy 36666.0 shares.
